These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunological analyses of human papillomavirus capsids. Giroglou T; Sapp M; Lane C; Fligge C; Christensen ND; Streeck RE; Rose RC Vaccine; 2001 Feb; 19(13-14):1783-93. PubMed ID: 11166904 [TBL] [Abstract][Full Text] [Related]
23. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Roth SD; Sapp M; Streeck RE; Selinka HC Virol J; 2006 Oct; 3():83. PubMed ID: 17014700 [TBL] [Abstract][Full Text] [Related]
24. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909 [TBL] [Abstract][Full Text] [Related]
25. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy. Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038 [TBL] [Abstract][Full Text] [Related]
26. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. Kohl TO; Hitzeroth II; Christensen ND; Rybicki EP BMC Biotechnol; 2007 Sep; 7():56. PubMed ID: 17850660 [TBL] [Abstract][Full Text] [Related]
27. A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. McClements WL; Wang XM; Ling JC; Skulsky DM; Christensen ND; Jansen KU; Ludmerer SW Virology; 2001 Oct; 289(2):262-8. PubMed ID: 11689049 [TBL] [Abstract][Full Text] [Related]
28. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Fleury MJ; Touzé A; Alvarez E; Carpentier G; Clavel C; Vautherot JF; Coursaget P Arch Virol; 2006 Aug; 151(8):1511-23. PubMed ID: 16508703 [TBL] [Abstract][Full Text] [Related]
29. High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16. Guan J; Bywaters SM; Brendle SA; Ashley RE; Makhov AM; Conway JF; Christensen ND; Hafenstein S Viruses; 2017 Dec; 9(12):. PubMed ID: 29211035 [TBL] [Abstract][Full Text] [Related]
30. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. Day PM; Gambhira R; Roden RB; Lowy DR; Schiller JT J Virol; 2008 May; 82(9):4638-46. PubMed ID: 18305047 [TBL] [Abstract][Full Text] [Related]
31. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962 [TBL] [Abstract][Full Text] [Related]
32. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies. Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404 [TBL] [Abstract][Full Text] [Related]
33. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid. Zhang C; Huang X; Chen S; Li Y; Li Y; Wang X; Tang J; Xia L; Lin Z; Luo W; Li T; Li S; Zhang J; Xia N; Zhao Q Vaccine; 2018 Oct; 36(45):6761-6771. PubMed ID: 30287156 [TBL] [Abstract][Full Text] [Related]
34. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development. Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615 [TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736 [TBL] [Abstract][Full Text] [Related]
36. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417 [TBL] [Abstract][Full Text] [Related]
37. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Thönes N; Müller M Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733 [TBL] [Abstract][Full Text] [Related]
38. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234 [TBL] [Abstract][Full Text] [Related]
39. Production and characterization of a novel HPV anti-L2 monoclonal antibody panel. Bywaters SM; Brendle SA; Biryukov J; Wang JW; Walston J; Milici J; Roden RB; Meyers C; Christensen ND Virology; 2018 Nov; 524():106-113. PubMed ID: 30170240 [TBL] [Abstract][Full Text] [Related]
40. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T J Virol; 1999 Jul; 73(7):6188-90. PubMed ID: 10364381 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]